Brief: Broward Health Medical Center Becomes First Clinical Site In U.S. For Phase Ii Trial For Lsalt Peptide
28/07/2020 13:54
July 28 (Reuters) - Arch Biopartners Inc ARCH.V :
* BROWARD HEALTH MEDICAL CENTER BECOMES FIRST CLINICAL SITE
IN
U.S. FOR PHASE II TRIAL FOR LSALT PEPTIDE
Source text for Eikon: ID:nGNX9v62k2
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide